NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non Hodgkin Lymphoma & Combined With Daratumumab for Multiple Myeloma

NKTR-255 is a cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects.

This is a Phase 1, open-label, multi-center, dose escalation, dose expansion, safety follow-up, and survival follow-up of NKTR-255 as a single agent and NKTR-255 in combination with DARZALEX FASPRO TM or rituximab. Study treatment is defined as any investigational treatment(s) or marketed product(s), intended to be administered to a study patient according to the study enrollment.

Part 1 will enroll relapsed/refractory MM and NHL patients. In Part 2, Cohort A will enroll NHL patients who have progressed on a chimeric antigen receptor T-cell (CAR-T) product, Cohort B will enroll MM patients who previously received daratumumab and other anti-CD38 therapies to receive NKTR-255 alone and/or in combination with daratumumab, and Cohort C will enroll iNHL patients who previously received rituximab and other therapies to receive NKTR-255 alone and/or in combination with rituximab.

SparkCures ID	1045
Trial Phase	Phase 1
Enrollment	118 Patients
Treatments	Daratumumab NKTR-255
Tags	Natural Killer (NK) Cells T Cell
Trial Sponsors	Nektar Therapeutics
NCT Identifier	NCT04136756

Key Inclusion Criteria:

Patients must have relapsed or refractory MM or NHL with no available therapies that would confer clinical benefit for their primary disease.
Measurable or detectable disease according to International Myeloma Working Group (IMWG) and the Lugano Classification. Extranodal NHL disease that is measurable by fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging only is allowed.
Estimated glomerular filtration rate (eGFR) ≥ 40 mL/min/1.73 m2.

Patient has the following laboratory test results during Screening:

Absolute neutrophil count (ANC) or absolute granulocyte count (AGC) ≥ 1000/µL
Platelets ≥ 30,000/µL
Hemoglobin ≥ 8g/dL
Absolute lymphocytes ≥ 500/µL
Leukocytes ≥ 3000/µL

Patients are eligible who also meet all the following criteria in these cohorts of Part 2:

Cohort A only:

• Patients with NHL who received a commercially approved CD19 CAR-T product and had PD. The first dose of NKTR-255 will be administered within 30 days of the PD.

Cohort B only:

Patients with MM must have had previous exposure to proteasome inhibitor, immunomodulatory agent (IMiD), and anti-CD38 therapy.
Patients who previously received daratumumab or other anti-CD38 therapies must have at least 3 months washout.

Cohort C only:

• Patients with relapsed or refractory iNHL who previously progressed during or following 1 or more prior systemic rituximab-containing (or another treatment with an anti-CD20 antibody-containing) regimens for lymphoma.

Key Exclusion Criteria:

Patients who have an active, known, or suspected autoimmune disease.
Any treatment-related neurotoxicity or cytokine release syndrome (CRS) prior to enrollment into the study should return to baseline before NKTR-255 treatment.
Active central nervous system (CNS) involvement with NHL.
Patients who have been previously treated with prior interleukin-2 or interleukin-15.
Patients who received daratumumab or other anti-CD38 therapies previously must have 3 months washout.
Patients who have had < 28 days since the last anti-cancer treatment, chemotherapy, biological therapy, or < 14 days from approved anti-myeloma agents, or systemic or inhaled steroid therapy at doses greater than 10 mg of prednisone or equivalent before administration of the first dose of study drug(s).
Prolonged Fridericia's corrected QT interval (QTcF) > 450 ms for men and > 470 ms for women at Screening.
Contraindication to or unable to receive daratumumab (Cohort B only)

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

The following criteria is provided for health care professionals.